clearn.png
Wednesday April 14th, 2021 7:32AM

Virios Therapeutics to Present at the Needham Virtual Healthcare Conference

By The Associated Press

ATLANTA--(BUSINESS WIRE)--Apr 7, 2021--

(Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that Greg Duncan, Chairman and Chief Executive Officer, and R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer, will present a company overview at the Needham Virtual Healthcare Conference on April 14, 2021 at 4:30 p.m. ET.

The presentation will focus on the need for new approaches to treat fibromyalgia (“FM”), the novel antiviral approach being pursued by Virios, and the potential of IMC-1 as an FM treatment, based on positive results from a Phase 2 proof of concept clinical trial. Management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A link to the live and archived webcast of the presentation may be accessed on Virios Therapeutics’ website under the Investors section: .

Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.

Evidence of IMC-1’s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2 clinical trial. These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia. IMC-1 has been granted fast track designation by the FDA and is currently being tested in a multi-center, randomized, double-blind, placebo-controlled Phase 2B trial designed to set the stage for registrational studies. The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies. For more information, please visit .

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com:

CONTACT: Dave Gentry

1-800-733-2447

+1-407-491-4498

[email protected]

or

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA GEORGIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Virios Therapeutics, Inc.

Copyright Business Wire 2021.

PUB: 04/07/2021 07:05 AM/DISC: 04/07/2021 07:05 AM

http://www.businesswire.com/news/home/20210407005092/en

  • Associated Categories: Associated Press (AP), AP Business, AP Business - Corporate News, AP Online - Georgia News, AP Business Wire - Georgia, AP Business - Industries, AP Business - Health Care
© Copyright 2021 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
UK Deliveroo riders to strike over pay, gig work conditions
Gig economy riders for app-based meal delivery platform Deliveroo are set to join strikes in 5 U.K. cities Wednesday over pay and working conditions
7:06AM ( 21 minutes ago )
Iran ship said to be Red Sea troop base off Yemen attacked
An Iranian ship believed to be a base for the paramilitary Revolutionary Guard anchored for years in the Red Sea off Yemen has been attacked
6:56AM ( 32 minutes ago )
3rd health minister fired in virus-hit Czech Republic
Czech Prime Minster Andrej Babis has fired his health minister, the third who has lost the job in the pandemic in one of the hardest-hit European countries
6:54AM ( 34 minutes ago )
Associated Press (AP)
EU agency to share results of probe into AstraZeneca shot
The European Medicines Agency will announce the conclusions of its investigation into the connection between AstraZeneca’s coronavirus vaccine and rare blood clots later on Wednesday
5:49AM ( 1 hour ago )
Global stocks mostly rise after lackluster day on Wall St
Global shares are mostly higher as progress on coronavirus vaccinations countered worries over flaring outbreaks in many countries
5:44AM ( 1 hour ago )
The Latest: UK starts administering Moderna vaccine
The U.K. is administering the first doses of the Moderna vaccine, the third authorized in the country against the coronavirus
4:45AM ( 2 hours ago )
AP Business
Japan's Toshiba studies acquisition proposal by global fund
Japan's Toshiba Corp. says it is carefully considering a preliminary acquisition proposal
2:54AM ( 4 hours ago )
Lawmakers call YouTube Kids a 'wasteland of vapid' content
A House subcommittee is investigating YouTube Kids
6:55PM ( 12 hours ago )
Bezos endorses higher corporate taxes for infrastructure
Amazon founder and CEO Jeff Bezos is endorsing President Joe Biden’s focus on building up the country’s infrastructure and says the company even supports a corporate tax rate hike to help pay for it
6:47PM ( 12 hours ago )
AP Business - Corporate News
The home of the Masters is a draw for basketball's best, too
It was April 7, 2003
2:33AM ( 4 hours ago )
Trae Young leads hot-shooting Hawks past Pelicans, 123-107
Trae Young scored 30 points and helped lead a third-quarter 3-point barrage as the surging Atlanta Hawks beat Zion Williamson and the New Orleans Pelicans 123-107
10:52PM ( 8 hours ago )
Nats finally play, beat Braves 6-5 on Soto's walk-off in 9th
Juan Soto drove in the winning run with a single on a 3-0 pitch in the bottom of the ninth inning to lift the coronavirus-depleted Washington Nationals to a 6-5 comeback victory over the Atlanta Braves after waiting five days to start their season
9:39PM ( 9 hours ago )
AP Online - Georgia News
AP Business Wire - Georgia
Asian stocks mixed after lackluster day on Wall Street
Asian shares are mixed after Wall Street took a breather, with major indexes edging lower
3:20AM ( 4 hours ago )
The Latest: India sees another record day of new virus cases
India has hit another new peak with 115,736 coronavirus cases reported in the past 24 hours
1:29AM ( 5 hours ago )
Asia Today: North Korea tells WHO it's still virus-free
North Korea has continued to claim a perfect record in keeping out the coronavirus in its latest report to the World Health Organization
12:48AM ( 6 hours ago )
AP Business - Industries
The Latest: Study: Moderna vaccine lasts at least 6 months
New research suggests the protection the Moderna vaccine gives against COVID-19 lasts for at least six months
12:20PM ( 19 hours ago )
The Latest: India could resume vaccine exports by June
The world’s largest vaccine maker, based in India, will restart exports of AstraZeneca doses by June if coronavirus infections subside in the country, its chief executive says
11:47AM ( 19 hours ago )
The Latest: Spain PM: Stepping up virus vaccination drive
Spain is stepping up its vaccination drive, according to Prime Minister Pedro Sánchez
10:58AM ( 20 hours ago )
AP Business - Health Care
UK Deliveroo riders to strike over pay, gig work conditions
Gig economy riders for app-based meal delivery platform Deliveroo are set to join strikes in 5 U.K. cities Wednesday over pay and working conditions
7:06AM ( 22 minutes ago )
Iran ship said to be Red Sea troop base off Yemen attacked
An Iranian ship believed to be a base for the paramilitary Revolutionary Guard anchored for years in the Red Sea off Yemen has been attacked
6:56AM ( 32 minutes ago )
3rd health minister fired in virus-hit Czech Republic
Czech Prime Minster Andrej Babis has fired his health minister, the third who has lost the job in the pandemic in one of the hardest-hit European countries
6:54AM ( 34 minutes ago )
The Latest: European regulator to explain blood clot probe
The European Medicines Agency will announce the conclusions of its investigation into the possible connection between AstraZeneca’s coronavirus vaccine and rare blood clots
6:50AM ( 38 minutes ago )
Main opposition party against mining wins Greenland election
Initial results show that Greenland’s main opposition party, which is against an international mining project involving uranium and other metals on the Arctic island, has emerged as the biggest party after winning more than a third of votes in an early parliamentary election
6:42AM ( 46 minutes ago )